The estimated Net Worth of Weihao Xu is at least $75.5 Mille dollars as of 16 December 2020. Weihao Xu owns over 6,000 units of CASI Pharmaceuticals Inc stock worth over $75,500 and over the last 4 years Weihao sold CASI stock worth over $0.
Sign up
Weihao Xu CASI stock SEC Form 4 insiders trading
Weihao has made over 1 trades of the CASI Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Weihao bought 6,000 units of CASI stock worth $15,420 on 16 December 2020.
The largest trade Weihao's ever made was buying 6,000 units of CASI Pharmaceuticals Inc stock on 16 December 2020 worth over $15,420. On average, Weihao trades about 6,000 units every 0 days since 2020. As of 16 December 2020 Weihao still owns at least 10,000 units of CASI Pharmaceuticals Inc stock.
You can see the complete history of Weihao Xu stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Weihao Xu's mailing address?
Weihao's mailing address filed with the SEC is C/O CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE, MD, 20850.
Insiders trading at CASI Pharmaceuticals Inc
Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over $0 worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth $51,898,666 . The most active insiders traders include Wei Wu He, Rajesh C Md Shrotriya e Pharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $6,141,555. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth $229,516.
What does CASI Pharmaceuticals Inc do?
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
What does CASI Pharmaceuticals Inc's logo look like?
Complete history of Weihao Xu stock trades at CASI Pharmaceuticals Inc
CASI Pharmaceuticals Inc executives and stock owners
CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Wei-Wu He,
Executive Chairman of the Board, Chief Executive Officer -
Alexander Zukiwski,
Chief Medical Officer -
Wei Zhang,
President, President of CASI China, Interim Principal Financial Officer -
Dr. Wei-Wu He Ph.D.,
Chairman & CEO -
Dr. Wei Zhang Ph.D.,
Pres & Principal Financial Officer -
Dr. Alexander A. Zukiwski M.D.,
Exec. VP & Chief Medical Officer -
James Huang,
Independent Director -
Y. Alexander Wu,
Independent Director -
Franklin Salisbury,
Independent Director -
Quan Zhou,
Independent Director -
Rajesh Shrotriya,
Independent Director -
Amanda Cui,
VP & Global Controller -
Dr. James E. Goldschmidt Ph.D.,
Chief Bus. Devel. Officer -
Sara B. Capitelli CPA,
VP of Fin. -
Byte Ltdsnow Moon Ltdtianji...,
-
Ken Ren,
CEO and Director -
Pharmaceuticals Inc Spectru...,
-
Alex Wu,
Director -
Tak W. Mak,
Director -
China Growth Fund Iii L.P.I...,
-
Strategy Holding Ltd Wealth,
10% owner -
Sara B Capitelli,
VP, Finance & PAO -
George Chi,
Chief Financial Officer -
Cynthia W. Hu,
See Remarks -
Byte Ltdsnow Moon Ltdtianji...,
-
Ken Keyong Ren,
Chief Executive Officer -
Larry Zhang,
President -
Weihao Xu,
Chief Financial Officer